AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of ... - PR Newswire (press release)
(3) AstraZeneca has investigated the use of SEROQUEL XR, an atypical antipsychotic, in the treatment of MDD, aiming to develop another potential treatment ...